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Risk Assessment for Developmental

Toxicity: Airborne Occupational
Exposure to Ethanol and Iodine
Donald R. Mattison*
Introduction
It has been estimated that 40% of the work force (more than 45
million) are women. 1 Approximately 75% are between 16 and 44
years old, and half of them are fertile. 2 The challenge to define the
impact of a chemical exposure on a woman and/or her fetus during
3
pregnancy is therefore common.
* Professor Mattison received his B.A. (Cum Laude) in chemistry and mathematics
from Augsburg College, his M.S. from M.I.T. and his M.D. from Columbia
University. He is the Dean of the Graduate School of Public Health at the University
of Pittsburgh and a member of the Editorial Advisory Board of RISK.
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OFFICE OF TECHNOLOGY ASSESSMENT, REPRODUCTIVE HEALTH HAZARDS IN THE

WORKPLACE (1985).
2

W. MOSHER & W. PRATT, FECUNDITY AND INFERTLTIY IN THE UNITED STATES

1965-1982 (National Center for Health Statistics PHS 85-1250 1985).
3 S. BARLOW & F. SULLIVAN, REPRODUCTIVE HAZARDS OF INDUSTRIAL
CHEMICALS: AN EVALUATION OF ANIMAL AND HUMAN DATA (1982); Mattison,

Hanson, Kochhar & Rao, Criteriafor Identifying and Listing Substances Known to
Cause Developmental Toxicity Under California'sProposition65, 3 REPRODUCTIVE
TOXICOLOGY 3 (1989) [hereinafter Criteria];Koren, Bologa, Long, Feldman &
Shear, Perceptionof TeratogenicRisk by Pregnant Women Exposed to Drugs and
Chemicals During the First Trimester, 160 AM. J. OBSTETRICS & GYNECOLOGY
1190 (1989); Mattison, Working, Blazak, Hughes, Killinger, Olive & Rao, Criteria
for Identifying and Listing Substances Known to Cause Reproductive Toxicity
Under California'sProposition65, 4 REPRODUCTIVE TOXICOLOGY 163 (1990)
[hereinafter Proposition 651; G. KOREN, MATERNAL-FETAL TOXICOLOGY: A
CLNICIANS GUIDE (1990).
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Yet, it is complicated by several factors. One is the assumption that
the processes involved in fetal development are the most exquisitely
vulnerable of all biological processes. This has led some employers to
exclude women from certain jobs4 and creates the concern that gender
bias may drive what is portrayed as attempts to protect the fetus. The
only way to approach this type of question is to clearly define the actual
vulnerability of the fetus, placenta, pregnant women, nonpregnant
women and men to all workplace exposures.
Clearly, definition of the biological process most sensitive to a
chemical exposure in an occupational setting is important. However,
workplace occupational exposures should be regulated to protect all
workers and all biological processes. Therefore, it is critically important
that rigorous scientific principles are followed in characterizing the
potential for harm.
In addressing the impact of occupational exposure on pregnancy or
fetal development it is important to understand how to characterize
chemicals that represent potential risks. Similarly, it is important to
identify chemicals that do not represent a risk. The purpose of this
report is to review the steps used in risk assessment for developmental
toxicity. Two chemicals for which airborne occupational exposure can
occur, ethanol and iodine, are used to illustrate the process and furnish a
basis for discussing approaches to the management of risks for
developmental toxicity in occupational settings.
Problems Facing Occupational Health Professionals
Approximately 90,000 chemicals are in use in the U.S.5 Between
3,000 and 4,000 of them have been tested for developmental
4 Mattison, Exclusion of Fertile Women From the Workplace: Bad Medicine,
Worse Law, 86 J. ARK. MED. SOC'Y 491 (1990).
5 OFIcE oF TEcHNoLoGY AssEssMENT, supra note 1.
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toxicity. 6 Therefore, for many occupational exposures, no data is
available.
Of the chemicals for which data are available, between 100 and
1,000, depending on the rigor of data analysis and interpretation, are
teratogenic in animals. 7 If the ratio of developmental hazards among
tested chemicals remains the same among chemicals not tested (between
1/30 and 1/3), then it can be estimated that between 3,000 and 30,000 of
the chemicals in use may be developmental toxicants in experimental
animals. Of. interest with respect to prediction of human risk,
approximately 30 chemicals are thought to be developmental toxicants in
humans. 8 If that ratio of risk for developmental hazard persists over
all chemicals, then about 1% of the chemicals in use (approximately
900) may be human developmental toxicants. To the extent this
reasoning is correct there are two conclusions; (1) most chemicals in use
have little potential for human developmental toxicity, and (2) chemicals
not yet identified as developmental toxicants may prove to be such.
6 J. SCHARDEIN, CHEMICALLY INDUCED BIRIH DEFECTS (1985); T. SHEPARD,
CATALOG OF TERATOLOGIC AGENTS (5th ed. 1986); STEERING COMMITEE (N
IDENTIFICATION OF TOxIc AND POTENTiALLY Toxic CHEMICALS FOR CONSIDERATION
BY THE NATIONAL TOXICOLOGY PROGRAM, BOARD ON TOXICOLOGY AND
ENVIRONMENTAL HEALTH HAZARDS, COMMISSION ON LIFE SCIENCES, NATIONAL
RESEARCH COUNCIL, TOXICITY TESTING. STRATEGIES TO DETERMINE NEEDS AND

PRiORTIEs (1984) [hereinafter ToxIcrrY TESnNG].
7 J. SCHARDEIN, supra note 6; T. SHEPARD, supra note 6; J. SEVER & R.
BRENT, TERATOGEN UPDATE. ENVIRONMENTALLY INDUCED BIRTH DEFECT RISKS

(1986).

8 Frankos, FDA Perspectives on the Use of Teratology Datafor Human Risk
Assessment,.5 FUND. APPL. TOXICOLOGY 615 (1985); Hemminki & Vineis,
Extrapolationof the Evidence on Teratogenicity of ChemicalsBetween Humans and
Experimental Animals: Chemicals Other Than Drugs, 5 TERATOGENESIS
CARCINOGENESIS & MUTAGENESIS 251 (1985); J. SCHARDEIN, supra note 6; T.
SHEPARD, supra note 6; J. SEVER & R. BRENT, supra note 7; Jelovsek, Mattison &
Chen, Predictionof Risk for Human Development Toxicity: How Important Are
Animal Studies?, 74 OBSTETRICS &GYNECOLOGY 624 (1989).
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How Should Occupational Exposures to Chemicals not
Characterized for Developmental Toxicity be Managed?
The above estimates suggest that approximately 900 chemicals in
commerce have the potential to be human developmental toxicants. How
should occupational exposures to chemicals which have not been
characterized for developmental toxicity be managed? Several different
options are available. One option would simply acknowledge the fact
that in absence of data characterizing the development toxicity of a
chemical, no male or female capable of reproducing should be exposed
to the chemical in a workplace setting. The exclusion of both men and
women of reproductive ages from exposure to uncharacterized
chemicals may appear to be the only rational method for protecting
human reproductive and developmental health.
Why exclude men of reproductive age from untested chemicals?
There is evidence demonstrating that reproductive and developmental
harm can result from paternal exposure. 9 Therefore, in the absence of
data defining male or female reproductive effects, or developmental
effects of the chemical, the only rational approach for the management
of the potential for risk is to exclude all workers of reproductive age if
anyone is to be excluded.
An alternative approach might be to manage occupational exposures
to chemicals which have not been tested adequately for reproductive
toxicity based on systemic toxicity. For example, if the dose associated
with systemic toxicity has been characterized and occupational
exposures are kept below the levels associated with systemic toxicity,
then it is reasonable to assume that toxicity to reproduction and fetal
development would be minimal.
Therefore, management of potential reproductive or developmental
risks resulting from occupational exposures to chemicals whose impacts
9 R. HOOD, DEVELOPMENTAL ToxIcoLOGY: RISK ASSESSMENT IN THE FuTuRE
(1990).
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on reproduction or development have not been characterized might
reasonably be approached by preventing systemic toxicity.
What is a Developmental Toxicant?
A developmental toxicant is a drug, chemical, virus, bacteria,
physical agent or deficiency state that alters morphology or subsequent
function of a developing organism. 10 Developmental toxicology is the
science which deals with the causes, mechanisms, manifestation and
prevention of developmental deviations of a structural or functional
nature which are produced by developmental toxicants.
Some developmental toxicologists think that any chemical, given in
large enough amounts can alter embryonic or fetal development. 1 1
However, existing data suggests that not all chemicals are
developmental toxicants. 12 As previously indicated, these data suggest
that between 1/30 and 1/3 of the chemicals tested are developmental
toxicants in experimental animals.
Of special interest is data suggesting that reproductive and
development endpoints are not always the most sensitive. Koeter 1 3
reviewed data from 37 chemicals tested for systemic, reproductive and
developmental toxicity. For about 1/3 of the chemicals, reproduction
was the most sensitive endpoint. For another 1/3 systemic toxicity
occurred in concert with developmental effects. Among the compounds
10 Stein, Kline & Kharrazi, What Is A Teratogen?, in 2 EPIDEMIOLOGIC CRITERIA
ISSUEAND REvIEwS IN TERATOLOGY 23 (H. Kalter ed. 1984); Fabro, On Predicting

Environmentally-inducted Human Reproductive Hazards: An Overview and
HistoricalPerspective, 5 FUND. APPL. TOxICOLOGY 609 (1985); J. SCHARDEIN,
supra note 6; T. SHEPARD, supra note 6; Criteria,supra note 3.
11 Karnofsky, Drugs as Teratogens in Animals and Man, 5 ANN. REV.
PHARMACOLOGY 447 (1965).
12 j. SCHARDEIN, supra note 6; T. SHEPARD, supra note 6; Frankos, supra note

8; Jelovsek, Mattison & Chen, supra note 8.

13 Koeter, Relevance of ParametersRelated to Fertility and Reproduction in
Toxicity Testing, in REPRODUCTiVE TOXICOLOGY 81 (D. Mattison ed. 1983).
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tested, 1/2 had no effect on reproduction or development at the minimal
effect level. Therefore, although reproduction and development are
critical endpoints for toxicological evaluation, not all chemicals will
adversely effect reproduction or development.
Risk Assessment for Developmental Toxicity
The process of risk assessment for developmental toxicity
incorporates four interrelated activities. 14 The first is hazard
identification: Can the chemical produce adverse developmental effects
in experimental animals or humans? If so, what type of effects are
produced and what is the period of development during which the
embryo or fetus is susceptible? The second step is hazard
characterization: What is the dose-response relationship and what is the
site and mechanism of action? It is important to recognize that doseresponse relationships in developmental toxicity can be complicated by
multiple competing endpoints, such as reduced fetal weight, disruption
of fetal development and fetal death. 15 The third step is exposure
assessment: What was the amount, duration, and timing of exposure,
and how much was absorbed and distributed to the fetus or placenta?
The fourth step is risk characterization: How likely is the exposure to
result in an adverse developmental outcome? 16
14

COMMrITEE ON THE INSTITUTIONAL MEANS FOR THE ASSESSMENT OF RISKS TO

PUBLIC HEALTH, COMMISSION ON LIFE SCIENCES, NATIONAL RESEARCH COUNCIL,

RISK ASSESSMENT IN THE FEDERAL GOVERNMENr. MANAGING THE PROCESS (1983)
[hereinafter RISK ASSESSMENT]; J. SCHARDEIN, supra note 6; Sheehan, Young,

Slikker, Jr., Gaylor & Mattison, Workshop on Risk Assessment in Reproductive
and Developmental Toxicology: Addressing the Assumptions and Identifying the
ResearchNeeds, 10 REGULATORY TOXICOLOGY AND PHARMACOLOGY 110 (1989).
15 Selevan & Lemasters, The Dose-Response Fallacy in Human Reproductive
Studies of Toxic Exposures, 29 J. OCCUPATIONAL MED. 451 (1987); J. KLINE, Z.
STEIN &

M.

DEVELOPMENT

SUSSER, CONCEPTION TO BIRTH. EPIDEMIOLOGY OF PRENATAL

(1989).

16 Schardein, TeratogenicRisk Assessment: Past,Present,and Future,in 1 ISSUES
AND REVIEWS INTERATOLOGY 181 (H. Kalter ed. 1983) [hereinafter TeratogenicRisk
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Finally, all of this information must be evaluated with a
characterization of the benefits of the exposure to arrive at a rational risk
management decision. Unfortunately, this rigorous process of analysis
has not been followed routinely in attempts to manage developmental
risks in the workplace. For example, little published data is available
which has explored the adverse effects which accrue to a woman and
her fetus from the loss of a job and subsequent loss of health benefits,
including prenatal care. In some occupational exposure settings, the loss
of income with subsequent impact on maternal and fetal nutrition and the
loss of health care benefits may produce substantially greater harm to the
fetus, mother and to the family than the continuing occupational
exposures.
Hazard Identification
The goal of hazard identification is to identify chemicals which
impair development before humans are exposed. Therefore, chemicals
are evaluated in experimental animals for their effect on development. If
they are developmental toxicants the data are used to set exposures
thought to protect human populations from developmental 'toxicity.
However, it may not be possible to identify all developmental toxicants
Assessment]; J. SCHARDEIN, supra note 6; Schardein, Schwetz & Kenel, Species
Sensitivities and Predictionof TeratogenicPotential,61 ENV'T HEALTH PERSP. 55
(1985) [hereinafter Species Sensitivities]; Fabro, supra note 10; Frankos, supra
note 8;-Wang & Schwetz, An Evaluation System of Ranking Chemicals with
Teratogenic Potential,TERATOGENESIS CARCINOGENESIS & MUTAGENEsIS 7:133

(1987); Hart, Reynolds, Krasavage, Ely, Bell & Raleigh, Evaluation of
Developmental Toxicity Data: A Discussion of Some Pertinent Factors and a
Proposal, 8 RISK ANALYSIS 59 (1988) [hereinafter Evaluation]; Kimmel,
Wellington, Farland, Ross, Manson, Chernoff, Young, Selevan, Kaplan, Chen,
Chitlik, Siegel-Scott, Valaoras & Wells, Overview of a Workshop on Quantitative
Models For Developmental Toxicity Risk Assessment, 79 ENV'T HEALTH PERSP.
209 (1989) [hereinafter Overview]; Criteria,supra note 3; Jelovsek, Mattison &
Chen, supra note 8; Jelovsek, Mattison & Young, Rules for Hazard Identification

in Developmental Toxicology, 42 TERATOLOGY 521 (1990).
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in animal models. For that reason, epidemiological studies are also
conducted to define human developmental effects of chemical
exposures. 17 This means that it is necessary to consider both animal
18
and human endpoints of developmental toxicity.
Developmental toxicity in animals is defined as the adverse effect of
a chemical on the conceptus. The adverse effects may be manifested
prenatally or postnatally. Developmental toxicity can include growth
retardation, functional deficits, structural malformation or death. 19
Manifestations of developmental toxicity observed in experimental
animals should not be expected to mimic those observed in humans
exposed to the same toxicant. Similarly, manifestations of
developmental toxicity observed in humans are not always reproduced
in experimental animals. The absence of uniformity of response is not
surprising, however, when the differences between human and
experimental animal exposure are considered. For example, differences
in dosage, placentation, metabolism, pharmacokinetics, critical periods
of development and durations of gestation can be expected to influence
the expression of developmental toxicity.
Human developmental toxicity also includes alteration of growth,
structure, function and death. It is important to recognize that these
endpoints may not be independent. For many developmental toxicants
17 M. BRACKEN, PERINATAL EPIDEMIOLOGY (1984); J. KLINE, Z. STEIN & M.

SUSSER, supra note 15.
18 Teratogenic Risk Assessment, supra note 16; J. SCHARDEIN, supra note 6;
Species sensitivities, supra note 16; Fabro, supra note 10; Frankos, supra note 8;
Wang & Schwetz, supra note 16; Evaluation, supra note 16; Criteria,supra note
3; Proposition 65, supra note 3; Mattison, Blann & Malek, Physiological
Alterations During Pregnancy: Impact on Toxicokinetics, to be published in
FuNDAM.NTAL& APPLIED TOXICOLOGY. Mattison & Jelovsek, Pharmacokinetics

and Expert Systems as Aids for Risk Assessment in Reproductive Toxicology, 76
ENV'T HEALTH PERSP. 107; Jelovsek, Mattison & Chen, supra note 8; Jelovsek,
Mattison & Young, supra note 16.
19 J. SCHARDEIN, supra note 6; 1985, T. SHEPARD, supra note 6; Wang &
Schwetz, supra note 16.
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there is a spectrum of adverse outcome. 2 0 At low doses a toxicant may
produce growth retardation. At higher doses disruption of fetal
development may occur, and at even higher doses, death. For additional
complexity, some investigators have suggested that exposures
associated with neural tube defects may prevent spontaneous abortion of
the malformed fetus. 2 1 However, recent data does not lend support to
that hypothesis. 22 Therefore, variability of outcome and severity of
effect is observed when developmental toxicity occurs. The sources of
this variability include differences in: dose, timing of exposure, maternal
and fetal susceptibility and interactions with other environmental factors.
It is important to note that structural defects resulting from exposure
to a developmental toxicant occur in characteristic patterns. 2 3
Furthermore, individual defect categories (especially when classified by
organ, system or body region) are etiologically and pathogenetically
heterogeneous. In addition, many adverse outcomes are measured and
classified in different ways in humans and experimental animals. This is
especially true for abnormalities of function such as learning and
behavior.
The classification of human structural abnormalities is different from
that used for the classification of animal abnormalities. Human structural
abnormalities are generally classified as malformations, disruptions, or
deformations. 24 These may have different pathogenic and etiologic
20 Selevan and Lemasters, supra note 15; K. JONES, SMITH'S RECOGNIZABLE
PATTERNS OF HUMAN MALFORMATION (4th ed. 1988); J. KLiNE, Z. STEIN & M.

SUSSER, supra note 15.
21 Roberts & Loyd, Area Differences in Spontaneous Abortion Rates in South
Wales and Their Relation to Neural Tube Defect Incidence, 4 BRIT. MED. J. 20
(1973).
22 Byme & Warburton, Neural Tube Defects in Spontaneous Abortion, 25 AM. J.
MED. GENETICs 327 (1986).
23 J. SCHARDEIN, supra note 6; T. SHEPARD, supra note 6; J. SEvER &R. BRENT,
supranote 7; K. JONES, supra note 20.
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implications than for structural abnormalities observed in animals.
Furthermore, some structural defects in humans and animals may be
considered to be normal variations with no clinical significance while
25
being important clues to mechanisms of abnormal development.
Timing of Exposure
A fundamental concept of developmental toxicology is that some
stages of embryonic development are more vulnerable than others. The
time of exposure to a developmental toxicant determines both sensitivity
to damage and the type of defect. Most developmental toxicants produce
their effects during specific critical developmental periods, which vary
across both compounds and species.
For some animal developmental toxicants, critical periods have not
been reliably established because treatment for toxicity testing continues
throughout pregnancy. For some however, detailed studies have been
conducted at different doses and times during pregnancy. 2 6 For these
chemicals, the critical period, sensitive developmental processes and
proposed mechanism of action can be described. 27 Specificity to
developmental stage has also been found where human developmental
toxicity has been studied in detail. 28
It is generally thought that exposure during the preimplantation or
presomite periods (0-14 days after fertilization) produces little
developmental toxicity because the conceptus either dies or regenerates
completely. Recent data, however, suggests that this hypothesis may be
incorrect. 2 9 These data suggest that preimplantation exposure to certain
24 Spranger, Bernischke, Hall, Lenz, Lowry, Opitz, Pinsky, Schwanzacher &
Smith, Errors of Morphogenesis: Concepts and Terms, 100 J. PEDIATRICS 160

(1982); K.JONES, supra note 20.
25
26
27
28

K. JONES, supra note 20; R. HOOD, supra note 9.
j. SCHARDEIN, supra note 6; T. SHEPARD, supra note 9.
R. HOOD, supra note 9.
j. SCHARDEIN, supra note 6; T SHEPARD, supra note 9.
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chemicals may indeed be followed by developmental toxicity.
During organogenesis (up to 60 days after fertilization) the human
embryo is highly sensitive to developmental toxicity and exposure to a
toxicant may produce morphologic and functional disruptions. After
organogenesis the fetus is less sensitive to morphologic alterations.
However, functional changes can occur in selected organs throughout
pregnancy and even after birth.
By the third trimester much of the structure of the fetus has been
defined. During this period and indeed after birth, many functional
characteristics are being developed. For example, cellular
communication is being developed, the cell number is increasing in
many organs and the patterns of gene expression are changing.
Therefore, the fetus (and the infant) remains vulnerable to cytotoxic or
disruptive processes during the third trimester (and after birth).
Hazard Identification with Incomplete Data
If there is no animal or human evidence available which addresses
the developmental hazard posed by a chemical, it may be impossible to
assess the risk of an exposure to a male or female. If, however, there
are any human reports or animal studies that suggest a possible hazard
or there are physical or chemical properties that would make the
compound more or less likely to be a hazard, it is important to proceed
further in calculating effect and exposure doses. 30
29 Rutledge & Generoso, Fetal Pathology Produced by Ethylene Oxide Treatment
of the Murine Zygote, 39 TERATOLOGY 563 (1989); Katoh, Cacheiro, Cornett, Cain,
et al., FetalAnomalies Produced Subsequent to Treatment of Zygotes with Ethylene
Oxide or Ethyl MethanesulfonateAre Not Likely Due to the Usual Genetic Causes,

210 MUTATION RESEARCH 337 (1989); Generoso, Katoh, Cain, Hughes, et al.,
Chromosome Malsegregation and Embryonic Lethality Induced by Treatment of
Normally OvulatedMouse Oocytes with Nocodazole,210 MUTATION RESEARCH 313

(1989); R. HOOD, supra note 9.
30 Jelovsek, Mattison & Young, supra note 16.
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If any animal studies have been conducted to characterize
developmental toxicity, it is important to establish the pattern of toxicity
in each animal species, as well as the highest no-observed-adverseeffect-level for each study. Are there any weaknesses of study design
that would lower confidence in the study? If there are human studies, it
is important to define the outcome for each and the timing of exposure
associated with that/ outcome. Often, however, lack of complete human
data makes interpretation difficult.
Implicit in this first step in risk assessment is the assumption that
developmental hazards identified in animals are predictive of
developmental hazard in humans. The converse, failure to demonstrate
developmental hazard, is also assumed to reflect safety following human
exposure. It is important to critically review the accuracy of this
assumption. 31
Frankos reviewed the concordance of animal and human data for 38
drugs reported to be developmental toxicants in humans and 165
reported not to produce developmental toxicity. 32 Of 38 drugs
identified as human teratogens, 37 were positive in at least one animal
species, and 29 were positive in more than one. Among 165 compounds
identified as nonteratogenic in humans, only 47 were negative in all
animal species tested.
Recent statistical analysis of the predictive power of developmental
toxicity testing in animals 33 has suggested that animal data is useful for
identifying human developmental toxicants. However, animal studies
are not determinative. A detailed collection of inferential rules used by
developmental toxicologists to interpret animal studies and assign hazard
31 J. SCHARDEIN, supra note 6; T. SHEPARD, supra note 9; Mattison & Jelovsek,
supra note 18; Jelovsek, Mattison & Chen, supra note 8; Jelovsek, Mattison &
Young, supranote 16.
32 Frankos, supra note 8.
33 Mattison & Jelovsek, supra note 18; Jelovsek, Mattison & Chen, supra note

8.
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for human developmental toxicity has been assembled. 34 In addition,
35
structure activity relationships are being explored.
Even if a chemical is determined to be a developmental hazard,
additional information is needed to define the actual risk. Further steps
include hazard characterization and exposure assessment, followed by
qualitative or quantitative risk assessment.
Hazard Characterization
At a minimum, hazard characterization requires demonstration of the
dose-response relationship for the developmental toxicant. For example,
what is the highest dose which produces no adverse developmental
effect? In addition, characterization of the smallest dose associated with
developmental toxicity is also critical to define the exposure or dose at
which no adverse human developmental effect is expected.
Given species differences in development, as well as the tendency
for animal studies to have a high false positive rate, 36 it is important to
have information on the site and mechanism of action of the
developmental toxicant. Like hazard identification, hazard
characterization also suffers from the lack of published peer reviewed
data. 37 As a result, even the minimal requirement for dose-response
information is often not available.
For a chemical identified as a developmental toxicant, it is important
34 Jelovsek, Mattison & Young, supra note 16.

35 Enslein, Lander & Strange, Teratogenesis: A Statistical Structure-Activity
Model, 3 TERATOGENESIS, CARCINOGENESIS. & MUTAGENEsIS 289 (1983); Braun,
New Perspectives in Tests for Teratogenicity, in 2 SAFETY EVALUATION AND
REGULATION OF CHEMICALS 230 (F. Homburger ed. 1985); R. HOOD, supra note 9;

Kavlock, Structure-Activity Relationships in the Developmental Toxicity of
SubstitutedPhenols: In vivo Effects, 41 TERATOLOGY 43 (1990).
36 Frankos, supra note 8; Mattison & Jelovsek, supra note 18; Jelovsek,
Mattison & Chen, supranote 8.
37 Barlow & Sullivan, supra note 1; ToxiciTy TESTING, supranote 6.
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to know if the effect is produced by the parent compound or
metabolites. What is the compound's absorption by likely routes of
exposure, the extent of placental transport, and the likely fetal exposure
at different maternal doses? 38 In addition, it is important to define
different levels of effect such as lowest-observed-effect level, the noobserved-adverse-effect level, and the maternal-toxic-effect level. These
help assess the likelihood that a given exposure is above or below the
39
threshold for developmental toxicity.
Exposure Assessment
In assessing exposure, it is important to determine if the amount and
duration was sufficient to cause an indirect or direct developmental
effect. If the exposure was at or near maternally toxic levels, or if the
exposed individual manifests toxic effects which result from the
exposure, then there is the possibility of an indirect effect whether or not
the compound is a developmental hazard. If the compound is a known
or suspected hazard, systemic toxicity suggests that the chemical(s) did
get into the maternal bloodstream and thus the fetus is presumed to be at
greater risk than if maternal toxicity was not observed. The route of
exposure and the absorption via that route considering gestational age
brings into play our knowledge of the physiology of pregnancy and its
likely effects on toxicokinetics. 4 0 All of this information is used to
estimate the amount of chemical which reached the fetus.
Because of unique windows of vulnerability for developmental
toxicity, exposure assessment requires accurate determination of dose,
38 R. HOOD, supra note 9.
39 Gaylor, Sheehan, Young & Mattison, The Threshold Dose Question in
Teratogenesis,8 TRATOLOGY 389 (1988).

40 Mattison, Physiological Variationsin PharmacokineticsDuring Pregnancy,in
DRUGAND CHEMICAL ACrIONIN PREGNANCY 37 (S. Fabro & Scialli eds. 1986);
Mattison, Transdermal Drug Absorbtion During Pregnancy, 33 CLINICAL
OBsTEmcs & GYNECOLOGY 718 (1990) [hereinafter TransdermalDrugAbsorption];
PhysiologicalAlterations, supra note 18.
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duration of exposure and the relationship of the exposure to
developmental milestones. If, for example, the exposure to and
clearance of the parent compound and any metabolites occurred prior to
conception, it is unlikely that any excess embryonic or fetal risk would
result.
Recognition of the existence of windows of vulnerability for
developmental toxicity also has implications for risk management for
occupational exposure settings. For example, if it is known that a
toxicant effects developmental processes occurring early in pregnancy,
one occupational risk management practice might be to remove women
attempting pregnancy from the workplace until after the sensitive
developmental stages have been completed. At that point work can be
resumed. It is also important to recognize that the physiological
alterations which occur during pregnancy may also act to minimize the
41
impact of occupational exposures on fetal development.
Risk Characterization
The final step of risk assessment, risk characterization, requires an
explicit formal method for translating developmental toxicity data in
animals and humans, estimates of time and duration of exposure and an
understanding of site and mechanism of action into an estimate of excess
risk. Methods have been developed for estimating human risk for
developmental toxicity from animal studies. 42 However, there is still
41 Mattison, supra note 40; Transdermal Drug Absorption, supra note 40;
PhysiologicalAlterations, supranote 18; Mattison & Jelovsek, supra note 18.
42 Evaluation, supra note 16; Butler & Kalasinski, Statistical Analysis of
EpidemiologicalData of Pregnancy Outcomes, 79 ENv'T HEALTH PERSPECT. 223

(1989); Faustman, Wellington, Smith & Kimmel, Characterization of a
Developmental Toxicity Dose-Response Model, 79 ENV'T HEALTH PERSPECT. 229

(1989); Gaylor, Quantitative Risk Analysis for Quantal Reproductive and
Developmental Effects, 79 ENV'T HEALTH PERSP. 243 (1989); Jelovsek, Mattison &
Chen, supra note 8; Jelovsek, Mattison & Young, supra note 16; Kimmel &
Gaylor, Issues in Qualitative and Quantitative Risk Analysis for Developmental
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disagreement on the validity of these methods because they are
probabilistic techniques which do not consider species differences in
development, nor do they consider differences in the site or mechanism
of action of developmental toxicants.
At this point the risk assessment and risk management procedures
becomes somewhat subjective because of the lack of an explicit
consensus for assigning the final risk and managing that risk. It is
important for the risk manager to recognize that not all pregnancies end
successfully. Even in the absence of exposure, approximately 15% of
pregnancies will end in clinically recognized spontaneous abortion and
2% to 5% of pregnancies will end with the birth of a child with a
congenital malformation. 43 Realization that not all pregnancies end at
term with the birth of a normal child is critical in understanding the
magnitude of any excess risk, as well as translating that information
clearly to employers and effected or potentially effected employees. In
addition, the quality and quantity of the data from which the estimates of
developmental risk are derived must also be characterized and
communicated to those individuals involved in the management of any
excess risk as well as effected employees.
Impact of Airborne Chemical Exposure on the Fetus
Using the approach outlined above, two chemicals for which
airborne occupational exposure can occur will be evaluated to
characterize risk to the fetus. The management of developmental risks
from these chemical exposures will be discussed. These two chemicals
were chosen because they allow illustration of the impact of several
different physiological changes during pregnancy on pharmacokinetics.
Toxicology, 8 RISK ANALYSIS 15 (1988); Kimmel, Perspectives on the Concern
For and Management of PrenatalChemical Exposure and PostnatalEffects, 562
ANN. N. Y. ACAD. SC. 1 (1989); Overview, supra note 16.
43 J.KLNE,Z. STEIN& M. SUSSER, supra note 15.
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In addition, they also point out the complexity of dealing with exposures
to substances which also may be a normal part of the nutritional
requirements of the body.
Table 144
Alterations in Pulmonary Function During Pregnancy
Nonpregnant

Pregnant

Respiratory rate
(respirations/min)

14-16

14- 16

Tidal Volume (ml)

500

700

Minute Ventilation
(L/min)

7.0 - 8.0

PulmonaryFunction

Volume exchange
(L/8 hrs)
(m3 /8 hrs)

3,360 - 3,840
3.36 - 3.84

9.8

-

11.2

4,704 - 5,376
4.70 - 5.38

In conducting the computations to determine exposure and dose it is
important to note that pregnancy is characterized by many physiological
changes including alterations in pulmonary function. 45 As seen above
in Table 1, these alterations in minute ventilation can have a substantial
impact on the amount of an airborne chemical delivered to the lungs of a
pregnant woman.
Iodine
Hazard Identification: Iodine is an integral part of the thyroid
hormones and as such is an essential micronutrient. The recommended
44 Modified from Mattison, supra note 40.
45 Mattison, supra note 40; Transdermal Drug Absorption, supra note 40;
PhysiologicalAlterations,supra note 18.
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daily allowance (RDA 1989) for iodine is 175 ptg/day. Iodine deficiency
and excess are both associated with developmental toxicity.46 Because
iodine and iodides are contained in a range of medicinals (elixirs and
expectorants) as well as topical bactericidials, a rather large literature has
developed concerning the developmental toxicity of iodine. In general,
these compounds have been shown to impact on fetal thyroid function
47
with large doses producing fetal hypothyroidism and fetal goiter.
Human epidemiological studies have suggested that there may be some
risk for eye and ear malformations. 4 8 However, that is only a
suggested association and has not been validated in other studies.
The target organs for iodine toxicity outside of the fetus include the
respiratory system, eyes, skin, central nervous system and
cardiovascular system. With inhalation exposure irritation of the eyes,
nose, lacrimation and headaches occur. Contact produces burning and is
associated with cutaneous hypersensitivity. Vomiting, abdominal pain
and diarrhea may also occur. Ingestion produces gastrointestinal burns
and tightness of the chest.
HazardCharacterization:Use of iodine-containing medications has
49
been associated with fetal goiter in approximately 400 infants.
Although other infants may have been affected and not reported. Doses
associated with fetal goiter are generally observed following chronic
treatment with iodine containing medications. However, it has been
recommended that if pregnant asthmatics respond only to iodine
containing medications the therapy should be continued during
pregnancy. Short courses of iodine (250 to 500 mg intravenously every
46 J. SCHARDEIN, supra note 6.
47 J. SCHARDEIN, supra note 6; T. SHEPARD, supra note 6.
48 O. HEINONEN, D. SLONE & S. SHAPIRO, BIRTH DEFECTS AND DRUGS IN

PREGNANCY (1983).
49 Burrow, Hypothyroidism in Pregnancy,298 NEwENGL. J. MED. 150 (1978); J.

SCHARDIN, supra note 6.

Mattison: Assessing Developmental Toxicity 245

6 hours for 2 to 7 days) have been used in preparation of hyperthyroid
pregnant patients for subtotal thyroidectomy without adverse effect on
the fetus. 50 The threshold for thyroid effects with chronic treatment
during pregnancy is below 12 mg/day.
Povidone-iodine is used as a vaginal disinfectant. Within 15 minutes
of the vaginal use of povidone iodine there is a 5 to 15 fold increase in
plasma inorganic iodide with levels remaining elevated for 60 minutes
after exposure. 5 1 This suggests that iodine can be absorbed across the
skin from organic iodine preparations. However, absorption across
vaginal epithelium is likely to be substantially more rapid and complete
than absorption across other dermal sites.52
Exposure Assessment: The OSHA permissible exposure limit for
iodine is 0.1 mg/m 3 or 0.1 ppm. Assuming that the airborne level
throughout an 8 hour work day remains fixed between 0.01 mgm 3 and
0.10 mg/m 3 and that all of the inhaled iodine is absorbed, then the dose
will be between 53.8 and 538 g.g/8 hour work day (Table 2 below).
Because of the pregnancy induced increase in tidal volume this is
somewhat more than the amount inhaled by the nonpregnant worker
(between 38.4 and 384 gg/8 hour work day). Note that all levels of
exposure at or below the OSHA permissible exposure limit are below
the lowest dose noted to alter fetal thyroid function and produce goiter
(12 mg/day53 ). However, exposures to airborne concentrations greater
than 0.03 mg/m 3 may produce total doses of iodine which are greater
than the recommended daily dietary allowance for pregnant women (175
jig/day).
50 Prout, Thyroid disease in pregnancy, 122 AM. J. OBSTETRICS & GYNECOLOGY
669 (1975); Burrow, supra note 48.
51 Vorheer, et al., Vaginal Absorption of Povidone-Iodine, 244 J.A.M.A. 2628

(1980).
52 Mattison, supra note 4; TransdermalDrug Absortion, supra note 40.

53 Burrow, supra note 48.
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Table 2
Pulmonary Exposure to Iodine During Pregnancy
Ambient air concentration
(mg/n 3 )

0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10

Iodine Absorbed (,uglday)t
Nonpregnant
Pregnant
38.4
76.8
115.2
153.6
192.0
230.4
268.8
307.2
345.6
384.0

53.8
107.6
161.4
215.2
269.0
322.8
376.6
430.4
484.2
538.0

tThe calculations assume that the ambient concentration remains constant for the 8
hour work day and that the volume exchange is 3.84 and 5.38 m3 per 8 hours in
nonpregnant and pregnant women, respectively.
Developmental Risk Characterization:Given that exposure via
dermal or pulmonary absorption is small and in the range of that
required for normal function of the thyroid, it seems unlikely that excess
risk for developmental toxicity will occur at doses up to the OSHA
permissible exposure limit. However, because it is possible to monitor
iodine levels (or thyroid hormones) in exposed workers, monitoring
would be an excellent adjunct to this assessment and is likely to be
reassuring. 54 Both pregnant and nonpregnant employees could be
54 NmIONAL RESEARCH COUNCIL, BIOLOGIC MARKERS IN REPRODUCTIVE

TOXIcOLoGY 15 (1989).
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monitored to assess the amount of iodine absorbed by all routes.
Developmental Risk Management: In this setting the risk manager
should explain the characteristic biphasic response for developmental
toxicity. Deficiencies in dietary iodine as well as excesses in iodine
exposure are both associated with an increased risk for adverse
developmental outcome. Iodine is also part of the normal diet and many
foods, including seafood, contain quite high levels of iodine. The levels
of exposure in this hypothetical occupational setting up to airborne
concentrations as high as 0.1 mg/m 3 assuming an 8 hour inhalation
exposure do produce daily doses that are greater than the recommended
daily dietary allowances for pregnancy. They are however, substantially
below the threshold for developmental toxicity in humans. This
threshold has been suggested for iodine containing medications
following the outcome of exposed human pregnancy. In summary,
iodine deficiency and excess can be associated with developmental
toxicity. The exposures evaluated in this example however, appear to be
substantially below the threshold for developmental toxicity observed in
humans. These data suggest that continued exposures to airborne
concentrations of iodine up to 0.10 mg/m 3 throughout pregnancy would
not be associated with any increased risk for developmental toxicity.
Ethanol
Hazard Identification: Studies in animals and humans have
identified ethanol as a developmental toxicant. 55 There is no question
that the offspring of alcoholic women who continue to consume large
amounts of alcohol during pregnancy are at risk for the Fetal Alcohol
Syndrome (FAS). FAS is characterized by altered growth,
55 Roman, Beral & Zuckerman, The Relationship Between Alcohol Consumption
and PregnancyOutcome in Humans, in 4 IssuES AND RviEwS iN TERATOLOGY 205
(H. Kalter ed. 1988); Blakley, Experimental Teratology of Ethanol,in 4 ISSUES AND
REVIEWS N TERATOLOGY 237 (H. Kalter ed. 1988).
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morphogenesis and function including (i) prenatal and/or postnatal
growth retardation, (ii) central nervous system involvement, (iii) facial
dysmorphology with at least two of the following, microcephaly, short
palpebral fissures or poorly developed philtrum, thin upper lip and/or
flattening of the maxillary area.
FAS is rare among the general population, varying between 0.04%
and 0.15% in different countries. Among women who abuse alcohol
during pregnancy, the risk of FAS has been reported to be as high as
32%. However, this may overstate the risk of FAS as the studies from
which these estimates are derived are confounded by unsystematic
ascertainment and clinical evaluation of the infant.
56
An early study using data from the Collaborative Periiatal Project
compared 23 alcohol abusers with 46 controls. Offspring of alcoholic
women were significantly shorter and lighter than controls. Offspring of
alcoholics also had an increased frequency of congenital anomalies and
lower IQ at age 7. Among these children, the risk of FAS was 32%.
Another study5 7 compared 223 infants of alcoholic women with
276 control children. Although the infants in this study were lighter and
shorter than controls there was no difference in congenital
malformations. A third study 58 evaluated 204 infants of alcoholic
women as part of a study evaluating birth outcome in 12,000
pregnancies. This study also demonstrated that these infants were small
and light compared to controls. Congenital malformations were
increased in these children, and 3% had stigmata of FAS.
Animal studies have demonstrated alcohol dose dependent increases
56 Jones, Smith, Streissguth & Myrianthopoulos, Outcome of Pregnancy in
Chronic Alcoholic Women, 1 LANCET 1076 (1974); Heinonen, Slone & Shapiro,

supra note 47.
57 Russell, Intrauterine Growth in Infants Born to Women with Alcohol Related
PsychiatricDiagnoses, 1 ALCOHOLISM 225 (1977).
58 Sokol, Miller & Reed, Alcohol Abuse During Pregnancy:An Epidemiologic
Study, 4 ALCOHOLISM 135 (1980).
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in embryo and fetal lethality, resorption, and stillbirth. 5 9
Malformations have been induced in all species studied with the
exception of rabbits. Malformations produced most consistently were
craniofacial disruptions resulting from central nervous system, ocular
and facial toxicity. The CNS disruptions observed included
anencephaly, exencephaly, hydrocephaly, microcephaly, neural tube
defects, agenesis of the corpus callosum, agenesis of the olfactory bulbs
and hypophyseal dysplasia. Ocular malformations included
anopthalmia, micropthalamia, coloboma, retinal disorganization and
ablepharia. The facial malformations observed included agnathia,
micrognathia, maxillary and mandibular hypoplasia, cleft palate, cleft
lip, microtia and low set ears. Other malformations have also been
observed.
These data indicate that ethanol is a developmental toxicant in
animals and humans. The next step is to explore the dose-response
relationship and site and mechanism of action.
Hazard Characterization:Among animal studies, alcohol dose
dependent increases in fetal toxicity and malformation have been
observed. Analysis of these dose-response studies suggest that blood
alcohol concentration is the most useful biomarker of risk for fetal
toxicity and malformation (Table 3).

59 Blakley, supra note 54.
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Table 360
Ethanol Blood Concentrations Associated with Fetal Toxicity
Min. Blood Alcohol (mg/L) Associated with Developmental Toxicity
Species
Perinatal Malformations
Intrauterine
Mortality GrowthRetardation
Mice
Rat
Dog
Monkey

730
610
1500
1300

430
610
1500
2000

730
610
1700
1600

The blood alcohol levels associated with fetal toxicity (mortality,
malformation, or growth retardation) falls into a range spanning two
orders of magnitude (approximately 100 to 1000 mg/L). In general,
chronic exposure associated with growth retardation occurs with alcohol
concentrations between 600 and 2000 mg/L in mice (Table 3).
Concentrations associated with malformations were between 400 and
2000 mg/L. Perinatal mortality has been reported at concentrations
between 600 and 2000 mg/L. The other observation these studies have
provided is that chronic low dose exposure is associated with greater
developmental toxicity than acute or subacute low dose exposure.
Although the data is somewhat conflicting, the proximate teratogen
or developmental toxicant is thought to be ethanol, although
acetaldehyde, a metabolite of ethanol, may also play a role in
60 Datafrom: Pierce & West, Alcohol Induced Microcephaly During the Third
Trimester Equivalent: Relationship to Dose and Blood Alcohol Concentration,3
ALCOHOL 185 (1986); Pierce & West, Blood Alcohol Concentration:A Critical
Factorfor ProducingFetalAlcohol Effects, 3 ALCOHOL 269 (1986); Bhldey, supra
note 54; Bonthius & West, Alcohol-induced Neuronal Loss in Developing Rats:
Increased Brain Damage with Binge Exposure, 14 ALCOHOL CLuN. ExP. RES. 107
(1990).
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developmental toxicity. The mechanism by which ethanol produces its
effect is thought to be by one of several routes including direct
embryonic cell damage, maternal malnutrition, fetal malnutrition,
depression of fetal and placental protein synthesis or fetal hypoxia. It is
also likely that ethanol exerts some of its adverse developmental effects
through paternally mediated toxicity. 61
Among humans the estimation of dose effect relationships for
developmental toxicity is somewhat more difficult than for experimental
animals. 62 Complicating factors include intermittent binge consumption
of alcohol and the effect of preconception and paternal exposure to
alcohol. As observed in experimental animals, the threshold for fetal
toxicity in humans also appears to depend to some extent on the
developmental endpoint considered. The most sensitive endpoint
appears to be growth, in which fetal toxicity is manifest by a decrease in
birth weight. Although some investigators have suggested that
premature separation of the placenta is the adverse effect with the lowest
61 R. HooD, supra note 9.
62 Mills, Graubard, Harley, Rhodes & Berendes, MaternalAlcohol Consumption
and Birth Weight. How Much Drinking During Pregnancy is Safe?, 252 J.A.M.A.

1875 (1984); Ernhart, Sokol, Martier, Moron, Nadler, Ager & Wolf, Alcohol

Teratogenicity in the Human:A DetailedAssessment of Specificity, CriticalPeriod,
and Threshold, 156 AM. J. OBSTETRICS & GYNECOLOGY 33 (1987); Marbury, Linn,
Monson, Schoenbaum, Stubblefield & Ryan, The Association of Alcohol
Consumption with Outcome of Pregnancy,73 AM. J. PUB. HEALTH 1165 (1983);
Stein & Kline, Smoking, Alcohol and Reproduction, 73 AM. J. PUB. HEALTH 1154.
(1983); Zuckerman & Hingson, Alcohol Consumption During Pregnancy: A
CriticalReview, 28 DEV. MED. & CHILD NEUROLOGY 649 (1986); Little, Moderate
Alcohol Use DuringPregnancy and DecreasedInfant Birth Weight, 67 AM. J. PUB.
HEALTH 1154 (1977); Hingson, Alpert, Day, Dooling, Kayne, Morelock,
Oppenheimer & Zuckerman, Effects of MaternalDrinking and Marijuana Use on
Fetal Growth and Development, 70 PEDIATRICS 539 (1982); Tennes & Blackard,
MaternalAlcohol Consumption, Birth Weight, and Minor PhysicalAnomalies, 138
AM. J. OBSTET. GYNECOL. 774 (1980); Streissguth, Barr, Sampson, Darby &
Martin, IQ at Age 4 in Relation to Maternal Alcohol Use and Smoking During
Pregnancy, 25 DEV. PSYCHOLOGY 3 (1989); Jones, Smith, Streissguth &
Myrianthopoulos, supra note 55.
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threshold dose. There appears to be no adverse effect of ethanol on fetal
growth when maternal consumption is below 1 to 2 oz (30 to 60 ml or
30 to 60 gms) of absolute alcohol per day. This also appeared to be the
threshold for premature placental separation. 63 One study suggested
that spontaneous abortion was the most sensitive endpoint with a
threshold for ethanol consumption of approximately 1 oz twice per
week. 6 4 Of interest, a study conducted in Paris 65 suggested that the
increased risk for growth retardation and stillbirth was seen almost
exclusively among beer drinkers. However, this effect may be due to
other life style factors among beer drinkers compared to women
drinking other alcoholic beverages. The more severe endpoints,
congenital malformations, spontaneous abortion and FAS appear to
require substantially higher alcohol consumption.
Exposure Assessment: These calculations assume that ambient
ethanol concentrations are between 250 ppm and 1000 ppm. Using
those assumptions plus information on pulmonary function it is possible
to calculate the maximum dose of ethanol from inhalation exposure
(Table 4). The calculations assume that exposure is constant and
continuous over an 8 hour work day, and all the inspired ethanol is
absorbed, not an unreasonable assumption as previous studies have
shown efficient pulmonary absorption.

63 Sokol, Miller & Reed, supra note 57; Association of Alcohol Consumption,

supra note 61.

64 j. KuNE, Z. STEIN & M. SUSSER, supra note 15.

65 Kaminski, Franc, Lebouvier, du Mazaubrun & Rumeau-Roquette, Moderate
Alcohol Use and Pregnancy Outcome, 3 NEUROTOXICOLOGY & TERATOLOGY
(formerly NEUROBEHAVIORAL TOXICoLOGy& TERATOLOGY) 173 (1981).
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Table 4
Pulmonary Exposure to Ethanol During Pregnancy
Airborne Ethanol
(ppm)
(m!/L air)
Volume exchange (L18 Hrs.)
Nonpregnant
Pregnant
PulmonaryEthanolDose
Nonpregnant
Pregnant

250
0.250 x 10-3

500
0.5 x 10-3

1000
1.0 x 10-3

3,840
5,376

3,840
5,376

3,840
5,376

1.0
1.4

1.9
2.7

3.8
5.4

Using these assumptions, exposure to an ambient concentration of
ethanol of 250 ppm represents a total pulmonary dose of 1.0 ml for the
nonpregnant worker and 1.4 ml for a pregnant worker. If the ambient
concentrations are higher, 500 or 1000 ppm, the total pulmonary dose
increases to 2.7 and 5.4 ml for a pregnant worker, exposed
continuously over an 8 hour working day.
Ethanol is distributed into body water, which increases substantially
during pregnancy. Ethanol is metabolized by hepatic alcohol
dehydrogenase. It is not known if ethanol metabolism changes during
pregnancy. 66 However, data from one study suggests that there is little
change in the rate of ethanol metabolism during pregnancy. 67

66 Mattison, supra note 40.

67 Idanpaan-Heikka, Jouppila, Akerblom, Isoaho, et al., Elimination and
Metabolic Effects of Ethanol in Mother, Fetus and Newborn Infant, 112 AM. J.
OBmTmcS

& GYNECOLOGy 387 (1972).
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Table 5

Impact of Changing Pulmonary Function and Body Water on Ethanol
Concentration During Pregnancy
Ambient Ethanol Concentration
250 ppm
500 ppm
1000 ppm
1.9
3.8
7.5t
2.6
5.3
10.5
Blood Ethanol Concentration

Dose Rate (mg/min)

Gestation

Maternal

Total

Weight

Body Water

(weeks)
0

(Kg)
50.0

(liters)

10

50.6

20

25.0

(mgIL)

4.39

8.66

25.5

2.19
2.50

5.00

11.88

54.0

27.0

2.84

5.67

11.22

30

58.5

29.0

2.64

5.27

10.45

40

62.5

33.0

2.32

4.64

9.18

t The dose rate (mg/min) is given for nonpregnant/pregnant women with respiratory
rates 7.5 or 10.5 L/min, respectively.

Using this data, with a one compartment pharmacokinetic model 68
it is possible to estimate the blood concentration of ethanol resulting
from pulmonary exposure (Table 5). In this calculation, the following
assumptions are made:
* the volume of distribution is approximately 0.5 L/kg
* the rate of ethanol intake from ambient air concentrations is
determined by the concentration (i.e., assuming 250 ppm that is
68 Mattison, supra note 40; PhysiologicalAlterations, supranote 18.
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equivalent to 0.250 mg/L of air), times the respiratory rate
(approximately 7.5 and 10.5 L/min in the nonpregnant and pregnant
woman, respectively)
- if all the ethanol inspired is absorbed through the pulmonary
epithelium, the dose rate will be approximately 1.9 and 2.6 mg/min in
the nonpregnant and pregnant woman, respectively
* the half-life of ethanol is about 20 minutes (ethanol is generally
cleared by zero order metabolism)
- with inhalation exposure, the time to steady state and steady state
ethanol concentrations can be approximated by a continuous infusion
model.
With a half-life of approximately 20 minutes, approximately 100
minutes of exposure is required to reach steady state concentrations of
ethanol in body water. If the ambient ethanol concentration is 250 ppm
then steady state concentrations would be 2.2 mg/L in a nonpregnant
woman and between 2.5 and 2.8 mg/L in pregnant women. With higher
ambient concentrations of ethanol the steady state concentrations would
obviously increase (Table 5).
DevelopmentalRisk Assessment
It is clear that high concentrations of ethanol will produce
developmental toxicity in experimental animals. Consumption of large
amounts of ethanol during pregnancy is also associated with human
developmental toxicity. Estimation of total ethanol dose, assuming all
the ethanol which is inspired is absorbed, gave total ethanol doses
between 1.4 and 5.4 ml/8 hour work day. In the human, 2 drinks per
day throughout pregnancy (approximately 1 oz or 30 ml of ethanol) is
thought to represent the threshold for developmental toxicity. The
estimated total dose of ethanol, with the assumptions stated above, is
below the threshold for human developmental toxicity. Simply
calculating the total dose, however, may be misleading because it is
believed that a more critical determinant of developmental toxicity is
2 RISK - Issues in Health &Safety 227 [Summer 1991]

blood alcohol concentration.
Most experimental animal studies using chronic ethanol exposure
have observed developmental toxicity at blood alcohol concentrations of
400 mg/L or greater (Table 3). Some studies, however, have observed
developmental effects at concentrations of 60 mg/L. Lower blood
ethanol concentrations are associated with growth retardation in
experimental animals, with higher concentrations producing
developmental disruption. The animal data is also consistent with a
threshold for developmental toxicity, with blood alcohol levels below 60
mg/L showing no developmental toxicity. The simulation, using a one
compartment pharmacokinetic model and assuming that inhalation
exposure can be approximated by a continuous infusion, gave estimated
maximum blood ethanol concentrations at ambient exposures of 250
ppm of about 2.5 mg/L at 10 weeks of pregnancy. If the ambient
concentrations are 500 ppm or 1000 ppm, maximum blood ethanol
concentrations would be 5 and 12 mg/L, respectively, in pregnant
women at 10 weeks gestation. These concentrations are substantially
below the lowest threshold concentration required for developmental
toxicity in experimental animals.
These data and simulations suggest that there is little if any risk from
exposures at an ambient concentration of 250 ppm. Even at a higher
airborne concentration (1000 ppm), the blood ethanol concentration
would be substantially below that associated with developmental toxicity
in experimental animals. If there is concern, however, that these
calculations may be incorrect, it would be a simple matter to measure
blood alcohol concentrations at the beginning and end of a work period
to determine the actual concentration. The use of a biomarker of ethanol
exposure (blood ethanol concentration) could be used to refine these risk
estimates. 69
69 NATIoNAL RESEARCH COUNCIL, supra note 53.
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Risk Management
In responding to questions about airborne ethanol exposure and
formulating a reasonable risk management policy, there are several
factors that a risk manager must understand. The first is that ethanol is a
known hazard for development and has been associated with
developmental toxicity in extensive studies conducted in both animals
and humans. These studies suggest that ethanol, rather than a metabolite
of ethanol, is responsible for the observed developmental toxicity. The
data also suggests that there is a clear threshold for adverse
developmental effects.
Characterization of a range of developmental toxic endpoints across
species suggests at the present time that blood ethanol concentrations
represent the best available biological marker for estimating
developmental risk. Although most studies suggest that the blood
ethanol concentration associated with developmental toxicity occurs
above 400 mg/L, some studies have suggested that developmental
toxicity may occur with ethanol concentrations as low as 60 mg/L.
Therefore, in these studies 60 mg/b was the threshold chosen for
comparing blood alcohol concentrations. Over the range of ethanol
concentrations in the air (250-1000 ppm), the maximum blood ethanol
concentration varied between 2.5 and 12 mg/L at 10 weeks of gestation.
Because ethanol produces cellular toxicity across a range of organs, it is
reasonable to minimize ethanol exposures throughout pregnancy. Note
that during pregnancy the increase in pulmonary function (vital capacity)
increases the dose of ethanol. However, also associated with pregnancy
is an increase in total body water. This produces a decrease in blood
ethanol concentration over the course of pregnancy. At all anibient air
concentrations up to 1000 ppm, over each of four time periods of
gestation for which the simulation was calculated (10, 20, 30 and 40
weeks), blood alcohol concentrations were substantially below the
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estimated threshold (60 mg/L). These calculations suggest that the
excess developmental risk, if any, to offspring of workers exposed to
airborne ethanol concentration up to 1000 ppm during pregnancy is very
small, if there is any excess risk. Workers should be reassured that
exposure under these conditions poses little risk to the fetus. Managers
should also be reassured that fetal vulnerability to ethanol exposures in
the workplace requires substantially higher levels of exposure.
Conclusions
The risk assessment methodology originally suggested for cancer 70
provides an important framework for assessing developmental risks and
organizing information for risk management. This risk assessment
framework requires three discrete steps to collect and organize data and
an additional step to calculate the excess risk. The first, hazard
identification, is the collection and organization of data demonstrating
the safety or hazard of the chemical or chemicals of concern in
experimental animal models and in humans. Although many compounds
have no data available for assessing developmental risk, it is important
to understand that, based on historical data, not all chemicals are
developmental toxicants. For those chemicals that produce
developmental toxicity, developmental endpoints are the most sensitive
for about a third of the chemicals. In addition, for many chemicals
associated with developmental toxicity the relative contribution from
maternal or paternal exposure remains to be defined. These are
important considerations for the risk manager in dealing with chemicals
whose developmental toxicity has not been characterized adequately.
The second step, hazard characterization, attempts to organize data
which defines the dose-response relationship between the chemical and
all adverse developmental endpoints. In addition, detailed information
70 RISK ASSESSMENT, supra note 14.
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about the site and mechanism of action, how the compound effects
development and how it produces its effect either as a parent compound
or after the formation of a metabolite is important for hazard
characterization. This data is critical, as compounds may be metabolized
by different routes across species with minimal or no formation of the
critical toxic metabolite in humans. Alternatively, humans may form the
critical developmental toxic metabolite which is not'formed in the animal
models used.
The third step, exposure characterization, is essential to define the
maximum amounts of chemicals to which humans are exposed during
pregnancy. In addition to simply defining the amount and duration of
exposure, it is also critical to determine the timing of exposure with
respect to the pregnancy milestones because of the unique windows of
vulnerability for adverse effects on development during pregnancy. This
timing of exposure with respect to pregnancy milestones may also be
very useful for management of certain developmental toxicants in 'an
occupational setting.
The final step in the quantitative risk assessment process uses the
data gathered and organized in the three previous steps to estimate either
quantitatively or qualitatively the developmental hazard resulting from
the occupational exposure. This final step results in a qualitative or
quantitative assessment of excess risk. In this step, data on site and
mechanism of toxicity, associations between dose or blood
concentrations and developmental toxicity are used along with human
exposure data to estimate excess risk, if any, that might accrue during
pregnancy from occupational exposures to the chenmical or chemicals of
concern.
After all of the above steps in qualitative or quantitative risk
assessment for developmental toxicity have been completed, it is
necessary for a risk management decision to be made. In the most
optimum settings the risk management decision is reached collectively
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by the people who will be impacted by the decision, including
employers and employees and perhaps other family members as well. It
is critically important to carefully define excess risk which results from
the occupational exposures of concern. However, it is also critically
important not to lose. sight of the benefits which result from
employment. Many of these benefits are tangible and quantifiable,
including income, purchasing power and health benefits.. Other
nontangible benefits from work can include the impact on self esteem
which results from being a productive member of society. Clear
characterization of risk from occupational exposures, as well as a clear
understanding of the benefits of continuing work are necessary before
an informed risk management decision can be made.
The risk assessment framework provides a structure for data
organization, data review and the calculation of any excess
developmental risk. It also provides the structure to be followed where a
causative association is suggested between an occupational or
environmental exposure and developmental toxicity.

